1Robert Putnak J,Coller B A,Vess G,et al.An evaluation of dengue type-2 inactivated,recombinant subunit,and live-attenuated vaccine candidates in the rhesus macaque model[J].Vaccine,2005,23(35):4442-4452.
2Liu W Q,Jiang H N,Zhou J M,et al.Recombinant dengue virus-like particles from Pichia pastoris:efficient production and immunological properties[J].Virus Genes,2010,40(2):53-59.
3Leng C H,Liu S J,Tsai J P,et al.A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity[J].Microbes Infect,2009,11(4):288-295.
4Kitchener S,Nissen M,Nasveld P,et al.Immunogenicity and safety of two live-attenuated teravalent dengue vaccine formulations in healthy Australian adults[J].Vaccine,2006,24(2):1238-1241.
5Sun W,Cunningham D,Wasserman S S,et al.Phase 2 clinical trial of three formulations of tetravalent live attenuated dengue vaccine in flavivirus-nave adults[J].Hum Vaccin,2009,5(1):33-40.
6Durbin A P,Whitehead S S,McArthur J,et al.rDEN4△30,a live attenuated dengue virus type 4 vaccine candidate,is safe,immunogenic,and highly infectious in healthy adult volunteers[J].J Infect Dis,2005,191(5):710-718.
7Zhu W Y,Qin C F,Chen S P,et al.Attenuated dengue 2 viruses with deletions in capsid protein derived from an infectious full-length cDNA clone[J].Virus Res,2007,126 (4):226-232.
8Morrison D,Legg T J,Billings C W,et al.A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults[J].J Infect Dis,2010,201(1):370-377.
